FDA Rejects “Not Approvable” Letters, Clarifies Efficacy Supplement
This article was originally published in The Tan Sheet
Executive Summary
FDA says industry concerns about the implied finality of "not approvable" letters led it to change how it responds to drug applications
You may also be interested in...
Schering-Plough’s Zegerid Switch Stumbles As FDA Questions Application
FDA indicated to Schering-Plough that the firm's Rx-to-OTC switch application for the proton pump inhibitor Zegerid is not ready for approval
Schering-Plough’s Zegerid Switch Stumbles As FDA Questions Application
FDA indicated to Schering-Plough that the firm's Rx-to-OTC switch application for the proton pump inhibitor Zegerid is not ready for approval
Schering-Plough’s Zegerid Switch Stumbles As FDA Questions Application
FDA indicated to Schering-Plough that the firm's Rx-to-OTC switch application for the proton pump inhibitor Zegerid is not ready for approval